Daniel P. Teufel

Daniel P. Teufel

Auto-generated profile, based on publicly available information

Daniel P. Teufel

BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DTDaniel P. Teufel
Daniel P. Teufel
SFStefan M. Freund
Stefan M. Freund
MBMark Bycroft
Mark Bycroft
AFAlan R. Fersht
Alan R. Fersht
The transcriptional coactivator p300 binds to and mediates the transcriptional functions of the tetrameric tumor suppressor p53. Both proteins consist of independently folded domains linked by intrinsically disordered sequences. A well studied short sequence of the p53 transactivation domain, p53(15–29), binds weakly to four folded domains of p300 [Taz1/cysteine–histidine-rich region 1 (CH1), Kix, Taz2/CH3, IBiD], with dissociation constants ( K D ) in the 100 μM region. However, we found that a longer N-terminal transactivation domain construct p53(1–57) bound tightly to each p300 domain. Taz2/CH3 had the greatest affinity ( K D = 27 nM) and competes with the N-terminal domain of Mdm2 for the p53 N terminus. p300 thus can protect the N terminus of p53 against the binding of other proteins. Mutations of p53 that abrogate transactivation (L22Q/W23S, W53Q/F54S) greatly weakened binding to each p300 domain, linking phenotypic defects to weakened coactivator binding. We propose a complex between tetrameric p53 and p300 in which four domains of p300 wrap around the four transactivation domains of p53.

13 April 2009 in Oncogene
Verified
Journal Article
Open access
PDF file
DTD P Teufel
D P Teufel
MBM Bycroft
M Bycroft
AFA R Fersht
A R Fersht
The transcriptional activity of the tumour suppressor, p53, requires direct binding between its transactivation domain (TAD, 1–57) and the transcriptional coactivator, p300. We systematically assessed the role of TAD phosphorylation on binding of the p300 domains CH3, Taz1, Kix and IBiD. Thr18 phosphorylation increased the affinity up to sevenfold for CH3 and Taz1, with smaller increases from phosphorylation of Ser20, Ser15, Ser37, Ser33, Ser46 and Thr55. Binding of Kix and IBiD was less sensitive to phosphorylation. Strikingly, hepta-phosphorylation of all Ser and Thr residues increased binding 40- and 80-fold with CH3 and Taz1, respectively, but not with Kix or IBiD. Substitution of all phospho-sites with aspartates partially mimicked the effects of hepta-phosphorylation. Mdm2, the main negative regulator of p53, competes with p300 for binding to TAD. Binding of Mdm2 to TAD was reduced significantly only on phosphorylation of Thr18 (sevenfold) or by hepta-phosphorylation (24-fold). The relative affinities of Mdm2 and p300 for p53 TAD can thus be changed by up to three orders of magnitude by phosphorylation. Accordingly, phosphorylation of Thr18 and hepta-phosphorylation dramatically shifts the balance towards favouring the binding of p300 with p53, and is thus likely to be an important factor in its regulation.

1 June 2011 in Journal of Molecular Biology
Verified
Journal Article
Closed access
DTDaniel P. Teufel
Daniel P. Teufel
CJChristopher M. Johnson
Christopher M. Johnson
JLJenifer K. Lum
Jenifer K. Lum
HNHannes Neuweiler
Hannes Neuweiler

23 March 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GMGemma Elizabeth Mudd
Gemma Elizabeth Mudd
ABAmy Brown
Amy Brown
LCLiuhong Chen
Liuhong Chen
KRKaterine van Rietschoten
Katerine van Rietschoten
SWSophie Watcham
Sophie Watcham
GBGavin S. Bennett
Gavin S. Bennett

11 April 2012 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
VBVanessa Baeriswyl
Vanessa Baeriswyl
HRHelen Rapley
Helen Rapley
LPLisa Pollaro
Lisa Pollaro
CSCatherine Stace
Catherine Stace
DTDan Teufel
Dan Teufel
CHChristian Heinis
Christian Heinis

15 February 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MEMatthias Eder
Matthias Eder
SPSilvia Pavan
Silvia Pavan
UBUlrike Bauder-Wüst
Ulrike Bauder-Wüst
KRKaterine van Rietschoten
Katerine van Rietschoten
ABAnn-Christin Baranski
Ann-Christin Baranski
DTDaniel P. Teufel
Daniel P. Teufel
Molecular imaging of cancers using probes specific for tumor-associated target proteins offers a powerful solution for providing information regarding selection of targeted therapy, patient stratification, and response to therapy. Here we demonstrate the power of bicyclic peptides as targeting probes, exemplified with the tumor-overexpressed matrix metalloproteinase MT1-MMP as a target. A bicyclic peptide with subnanomolar affinity towards MT1-MMP was identified, and its radioconjugate showed selective tumor uptake in an HT1080 xenograft mouse model. Proteolytic stabilization of the peptide by chemical modification significantly enhanced the in vivo tumor signal [from 2.5%ID/g to 12%ID/g at 1 hour post injection (p.i.)]. Studies using mouse xenograft models with different cell lines show a robust correlation between tumor signals and in vivo MT1-MMP expression levels. Fatty acid modification of the bicyclic peptide extended its circulating half-life, resulting in increased tumor signals (36%ID/g at 6 hours p.i.). Comparative work with an equipotent radiolabeled MT1-MMP targeting antibody demonstrated starkly differential biodistribution and tumor accumulation properties, with the tumor signal slowly increasing to 6.2%ID/g within 48 hours. The rapid tumor penetration characteristics of bicyclic peptides, coupled with high potency and chemical versatility, thus offer high-contrast imaging probes for clinical diagnostics with compelling additional potential in targeted therapy. Significance: This work demonstrates the potential of bicyclic peptides as a platform for the development of high-contrast imaging probes for potential use in clinical cancer diagnostics and molecularly targeted therapeutics.